Clinical trial NCT06602531: Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults
Official title: A Phase 1, First-in-human, Randomized, Observer-blind, Parallel Design, Controlled, Dose Level and Schedule-finding Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Self-Amplifying MRNA Pandemic Influenza Vaccine (ARCT-2304) When Administered to Healthy Adults
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Influenza, Human
Keywords: Influenza
Vaccine
Lead sponsor: Arcturus Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2024-09-19
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The goal of this clinical trial is to evaluate the safety and immune responses of three different dose levels a self-amplifying RNA pandemic influenza vaccine (ARCT-2304) in adults. The key objectives of the study are:

* To evaluate safety and reactogenicity of different dose levels of the ARCT-2304 vaccine
* To describe the Immune responses of different dose levels of the ARCT-2304 vaccine as measured by hemagglutination inhibition (HAI) and neuraminidase enzyme-linked lectin (ELLA) antibody responses

Researchers will compare the results with licensed influenza vaccines to select the most optimal dose level and schedule for vaccine administration in terms of safety and immunogenicity for further development of the vaccine.

Participants will receive 2 doses of the ARCT-2304 vaccine or 1 dose of licensed influenza vaccine and 1 dose of placebo.

They will be asked:

* to complete a daily diary for 7 days after each vaccination, answering questions how they have been feeling on that day.
* to provide blood samples at each visit in the clinic
* to comply with all study visits and procedures (e.g., be available for planned telephone contacts and unscheduled clinic visits, if required)

Detailed description: Phase 1, first-in-human, randomized, controlled, observer blind, dose level and schedule-finding study, to evaluate the safety, reactogenicity, and immunogenicity of a self-amplifying mRNA pandemic influenza (H5N1) vaccine (ARCT-2304) when administered as a 2-dose vaccination series to healthy adults in comparison with an inactivated influenza vaccine.

Study drug (ARCT-2304 or control) will be administered as a 2-dose vaccination series as an intramuscular (IM) injection. The study comprises two parts.

In Part 1, 120 participants (young adults) will be randomized to one of the three dose levels of the ARCT-2304 vaccine or control vaccine. Participants will be further randomized to one of the two different vaccination schedules.

In Part 2, 80 participants (older adults) will be randomized to one of the three dose levels of the ARCT-2304 vaccine or control vaccine. Participants will be further randomized to one of the two different vaccination schedules.

Investigational Vaccine: ARCT-2304

Control Vaccines: licensed influenza vaccines

Eligibility criteria: Main Inclusion Criteria:

* Individuals are male or female adults 18-80 years of age.
* Healthy participants or participants with pre-existing stable medical conditions.
* Individuals of childbearing potential must be willing to adhere to contraceptive requirements.

Main Exclusion Criteria:

* Individuals with acute medical conditions or febrile illness, including body temperature ≥100.4°F (≥38.0°C measured by any method) within 3 days prior to randomization.
* Individuals with a known history of severe hypersensitivity reactions, including anaphylaxis, or other significant adverse reactions to any mRNA vaccine, influenza vaccine, or excipients.
* Individuals with a history of myocarditis, pericarditis, myopericarditis, or cardiomyopathy.
* Individuals who received any influenza vaccine within 3 months prior to first vaccine administration or plan to receive an influenza vaccine during the study period.
* Individuals who have received mRNA vaccination within 60 days before the first vaccine administration.
* Individuals who have received or plan to receive an A/H5N1 influenza vaccine and/or individuals who had substantial exposure to or direct contact with poultry, wild birds, live cattle, or raw milk.

Primary outcomes:
measure: Percentage of participants reporting local Adverse Events
timeFrame: For 7 days following each study vaccination
measure: Percentage of participants reporting systemic Adverse Events
timeFrame: For 7 days following each study vaccination
measure: Percentage of participants reporting unsolicited Adverse Events
timeFrame: For 28 days following each study vaccination
measure: Percentage of participants reporting laboratory or vital signs abnormalities
timeFrame: For 28 days following each study vaccination
measure: Percentage of participants reporting serious adverse events, medically attended adverse events, adverse events of special interest, and adverse events leading to early termination
timeFrame: For 28 days following each study vaccination
measure: Serum hemagglutination inhibition (HAI) antibody levels against the HA glycoprotein
timeFrame: For 28 days following study second vaccination
measure: Serum neuraminidase enzyme-linked lectin (ELLA) assay antibody levels against the NA glycoproteins
timeFrame: For 28 days following study second vaccination
Secondary outcomes:
measure: Percentage of participants reporting serious adverse events, medically attended adverse events, adverse events of special interest, and adverse events leading to early termination
timeFrame: For 240 days following study vaccination
measure: Serum hemagglutination inhibition (HAI) antibody levels against the HA glycoprotein
timeFrame: For 240 days following study vaccination
measure: Serum neuraminidase enzyme-linked lectin (ELLA) assay antibody levels against the NA glycoproteins
timeFrame: For 240 days following study vaccination
measure: Serum neutralizing (MN) antibody levels against the HA glycoprotein
timeFrame: For 28 days following study second vaccination
Other outcomes:
Locations:
Study officials:
affiliation: Arcturus Therapeutics
name: Clinical Program Director
role: STUDY_DIRECTOR
References: